预防肝硬化首次失代偿的药物治疗
肝硬化影响全球超过1亿人,与门静脉高压和肝失代偿相关的发病率和死亡率显著。目前唯一获批用于预防肝失代偿的药物仍是非选择性β受体阻滞剂,多种药物正在临床前和临床试验中评估预防首次肝失代偿的疗效。本叙述性综述讨论肝硬化治疗的现状、潜在新治疗靶点及未来方向。
要点
- 全球超过1亿人受肝硬化影响,发病率和死亡率与门静脉高压和肝失代偿相关。
- 目前唯一获批用于预防肝失代偿的药物类别仍是非选择性β受体阻滞剂。
- 多数研究评估反映疾病严重度和门静脉高压的主要终点,如HVPG变化或基于组织学或影像的纤维化分期。
核心结论
- 许多药物正在研究中,但仍需大量工作来确定具有有效结局的治疗靶点,以推动肝硬化管理领域的进展。
研究设计与样本
- 叙述性综述,讨论肝硬化治疗的现状、潜在新治疗靶点及未来方向。
主要发现
- 肝硬化影响全球超过1亿人,与门静脉高压和肝失代偿相关的发病率和死亡率显著。
- 当前治疗主要针对早期识别慢性肝病并通过治疗肝病病因来预防纤维化进展。
- 晚期纤维化患者的治疗选择有限,唯一获批用于预防肝失代偿的药物类别仍是非选择性β受体阻滞剂。
- 多种药物正在临床前和临床试验中开发,以探索预防首次肝失代偿的疗效。
- 多数研究评估反映疾病严重度和门静脉高压的主要终点,如HVPG变化或基于组织学或影像的纤维化分期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhosis is a prevalent condition affecting more than 100 million people globally and carrying significant morbidity and mortality related to the development of portal hypertension and hepatic decompensation. Current treatment is primarily targeted at identifying chronic liver disease early and preventing the progression of fibrosis by treating the underlying etiology of liver disease. Treatment options for patients with advanced fibrosis are limited, and the only drug class approved for the prevention of hepatic decompensation remains nonselective beta-blockers. There are several pharmacological therapies being developed in both preclinical and clinical trials to explore their efficacy in preventing first hepatic decompensation. Most studies evaluate primary endpoints reflective of disease severity and portal hypertension, such as changes in HVPG or fibrosis stage based on histology or imaging. While many drugs are being investigated, much work is still needed to identify treatment targets with effective outcomes to move the needle in the field of cirrhosis management. This narrative review will address the current state of cirrhosis therapies, including potential new therapeutic targets, and provide direction on future advancements that will improve our current treatment paradigm and lead to better outcomes for those burdened with cirrhosis.
引用
- Kezer CA, Berzigotti A, Fortune BE, et al. Drug treatments to prevent first decompensation in cirrhosis. Hepatology. 2024. PMID: 39378416. doi:10.1097/HEP.0000000000001117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。